Research in Brief.

Abstract

The humanised anti-IL-17A and IL-17F monoclonal antibody bimekizumab might be a safe and effective treatment option for patients with psoriatic arthritis who have either never received biological disease-modifying antirheumatic drugs (DMARDs) or who have had a previous inadequate response or intolerance to tumour necrosis factor (TNF) inhibitors, according to two multicentre, phase 3, double-blind trials (BE OPTIMAL and BE COMPLETE). In BE OPTIMAL, Iain McInnes and colleagues randomly assigned 852 patients with psoriatic arthritis who were naive to biological DMARDs (3:2:1, stratified by region and bone erosion at baseline) to receive 160 mg subcutaneous bimekizumab every 4 weeks, placebo every 2 weeks, or 40 mg adalimumab every 2 weeks for 16 weeks.